tiprankstipranks
Trending News
More News >

Replimune price target raised to $22 from $21 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Replimune (REPL) to $22 from $21 and keeps a Buy rating on the shares. The firm expects a relatively uneventful FDA review process for RP1.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue